ZBD0276, a class 1 new drug against idiopathic pulmonary fibrosis, was accepted for clinical trial

2021-04-18 15:19:00
On June 2, Heilongjiang ZBD Company (hereinafter referred to as ZBD) announced that the company's anti-idiopathic pulmonary fibrosis class 1 innovative drug tablet ZBD0276 has received the "Notice of Clinical Trial Acceptability" issued by the State Drug Administration, and clinical related work can be carried out after the approval of the review.
 
ZBD owns independent intellectual property rights of the ZBD0276 tablets (5mg, 20mg, 100mg) accepted for clinical trial this time.It is a continuous force for ZBD to expand innovative research and development in the field of chemical medicine and major diseases such as respiratory system.

 

It is understood that IPF is a chronic, progressive and fibrotic interstitial lung disease, which tends to occur in middle-aged and elderly people.According to statistics, the prevalence of IPF in the whole population is about (2-29) / 100,000 every year, and it is estimated that the proportion will gradually increase at 11%/ year.As a chronic interstitial lung disease, IPF has insipid onset, gradual or acute exacerbation.The average survival after diagnosis of IPF is only 2.8 years, and the mortality rate is higher than that of most tumors, so it is called a "tumor-like disease".
 
The pathogenesis of IPF is complex and has not yet been fully elucidated, but there is evidence that it is related to immune inflammatory injury.Preclinical studies have shown that ZBD0276 tablets can improve pulmonary inflammation and fibrosis by inhibiting inflammation and fibrosis pathway Th1/Th2 and transforming growth factor TGF-β, thereby inhibiting the production of inflammation and fibrosis.
 
According to statistics, there are only two approved effective treatments for IPF at present, among which Roche Pharmaceuticals' pirfenidone is the world's first marketed treatment for IPF, with a domestic sales volume of 242 million yuan in 2019.Ifinidone from Guangdong East Sunshine Pharmaceutical Co., Ltd is under phase I clinical study.In animal model evaluation, the efficacy of ZBD0276 in vivo is better than that of similar listed control drugs, and it has good safety, medicinal properties and clinical development value.In the current "blue ocean" situation, the development prospect of ZBD0276 pieces is optimistic, the market performance is predictable.
 
Only 2 weeks, including ZBD0276 piece and influenza type 1 new drugs for injection HNC042 treasured island, two 1 kind of innovative drugs are important progress, is the company to build a high level of Chinese medicine, chemical medicine and biological medicine research and development achievements have been made constantly cluster technology platform and high-tech products of solid, treasured island in the future will continue to increase in view of the major disease medicine, biological medicine research and development strength and range of cooperation, the innovation research and development into the company the most robust development momentum.